Abstract
The chronic asthma is characterized by the inflammation of the airways brought on by an overabundance of T helper cell type 2 (Th2) responses. All therapy, which included the inhaling synthetic glucocorticoids, is only able to manage the Th2-driven chronic eosinophilic inflammation; it is unable to alter the body's immunological tolerance to the outside antigens. The primary cells which regulates the immune response are the regulatory T cells, or Tregs. The Tregs cells are essential for controlling the autoimmune, allergy, and different immune process. The basic traits of Tregs is known as immunomodulatory processes, this review included the Tregs' advancements in the treatment of asthma. As more as research on Treg regulation mechanisms will lead to improved asthma medications and management techniques.